Morepen Laboratories Board to Approve FY26 Results on May 22

Morepen Laboratories' consolidated revenue stood at ₹385 crore in Q3 FY26, with Profit After Tax at ₹41 crore.

Reader Takeaway: Revenue up 10.6% in Q3; full-year results to confirm FY26 growth trajectory.

What just happened (today’s filing)

Morepen Laboratories Ltd. has announced its Board of Directors will convene on May 22, 2026.

The primary agenda is to review and approve the audited standalone and consolidated financial results for the fiscal year ending March 31, 2026.

Concurrently, the company has informed that its trading window for securities will be closed from May 23, 2026, up to and including May 24, 2026.

Why this matters

This announcement signals the final stages of the financial year's reporting cycle. Investors are keenly awaiting the audited full-year performance figures.

The upcoming results will provide a comprehensive view of the company's financial health, profitability, and operational efficiency throughout FY26.

The backstory (grounded)

Morepen Laboratories operates in the pharmaceutical sector, with core business segments including Active Pharmaceutical Ingredients (APIs), finished formulations, and diagnostics. The company is known for brands like Burnol and Lemolate.

Recent performance provides context: in the third quarter of FY26, consolidated revenue saw a healthy 10.6% year-on-year jump to ₹385 crore. Profit After Tax also climbed to ₹41 crore from ₹30 crore in the prior year's comparable period.

What changes now

Shareholders and investors must now wait for the official declaration of the full-year financial results.

The period of trading restrictions means company insiders are restricted from transacting in its shares until the results are disseminated.

Risks to watch

(No specific risks mentioned in the filing. Generic risks for pharma sector apply, such as regulatory changes, pricing pressures, and raw material cost volatility.)

Peer comparison

Morepen Laboratories operates in a competitive landscape. Key peers include Divi's Laboratories Ltd., a major player in APIs and custom synthesis, and Aarti Drugs Ltd., which focuses on APIs and pharmaceutical intermediates.

While Divi's Laboratories reported robust Q3 FY26 financials with revenue of ₹2,226 crore and PAT of ₹613 crore, Aarti Drugs posted Q3 FY26 revenue of ₹653 crore and PAT of ₹42 crore.

Context metrics (time-bound)

• Morepen Laboratories' consolidated revenue was ₹385 crore for Q3 FY26.
• The company reported a consolidated Profit After Tax of ₹41 crore for Q3 FY26.
• Consolidated revenue for the company grew by 10.6% year-on-year in Q3 FY26.

What to track next

• The formal declaration of Morepen Laboratories' audited standalone and consolidated financial results for FY26 on May 22, 2026.
• Analysis of the full-year revenue, profit, and margin trends.
• Management's commentary on future outlook and strategic priorities during the post-results communication.
• The company's performance relative to its peers like Divi's Laboratories and Aarti Drugs.